Partnership strengthens Nugevia™ launch bringing clinical and scientific integrity to the fast-growing longevity space ...

Women’s Health Collective Canada (WHCC) is proud to announce the launch of Vital Talks, a new national online seminar series bringing together leading researchers, clinicians, and voices with lived ...

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up. Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG ...

AdCare Rhode Island has been a vital part of this community for many years, and I am honored to have the opportunity to lead our team into the future,” Paliotti said. “This is such an exciting time, ...

De la ménopause aux menstruations et plus encore, Conversations vitales fournit des renseignements scientifiques importants aux femmes à chaque étape de leur parcours de santé TORONTO, 15 sept. 2025 ( ...

Of the laboratory’s accreditation, Dr. Jordan Olson, Chief Medical Officer and Chair of Pathology at HNL Lab Medicine, said: “Our community depends on accurate, timely, and reliable laboratory testing ...

With more than 40,000 patients treated so far, Smile Hair Clinic continues to be a pioneer in the field of advanced hair transplantation with natural-looking results and cutting-edge technology.

WASHINGTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- On Sept. 10, more than 50 citizen lobbyists representing a consortium of 15 national nonprofits and organizations gathered on Capitol Hill for the first ...

Villepinte, le 15 septembre 2025, 17h45 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce une révision à la baisse de ses ...

Villepinte, 15 September 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial ...

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced a poster ...

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces that the final results ...